Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124:901–5.

Article  PubMed  Google Scholar 

Hartmann A. Postmortem studies in Parkinson’s disease. Dialogues Clin Neurosci. 2004;6:281–93.

Article  PubMed  PubMed Central  Google Scholar 

Surmeier DJ. Determinants of dopaminergic neuron loss in Parkinson’s disease. Physiol Behav. 2017;176:139–48.

Google Scholar 

Nguyen M, Wong YC, Ysselstein D, Severino A, Krainc D. Synaptic, mitochondrial, and lysosomal dysfunction in Parkinson’s disease dopaminergic neurodegeneration in PD. Trends Neurosci. 2019;42:140–9.

Article  CAS  PubMed  Google Scholar 

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:1–21.

Article  Google Scholar 

Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011;1:a008862.

You H, Mariani LL, Mangone G, Le Febvre de Nailly D, Charbonnier-Beaupel F, Corvol JC. Molecular basis of dopamine replacement therapy and its side effects in Parkinson’s disease. Cell Tissue Res. 2018;373:111–35.

Article  CAS  PubMed  Google Scholar 

Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol. 2015;132:96–168.

Article  CAS  PubMed  Google Scholar 

Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs. 2016;76:759–77.

Article  CAS  PubMed  Google Scholar 

Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18:435–50.

Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, De Bie RMA, et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review. J Neurol. 2013;260:2701–14.

Article  PubMed  PubMed Central  Google Scholar 

Kikuchi T, Morizane A, Doi D, Magotani H, Onoe H, Hayashi T, et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model. Nature. 2017;548:592–6.

Article  CAS  PubMed  Google Scholar 

Axelsen TM, Woldbye DPD. Gene therapy for Parkinson’s disease, an update. J Parkinsons Dis. 2018;8:195–215.

Article  PubMed  PubMed Central  Google Scholar 

Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, et al. Subthalamic GAD gene therapy in a Parkinson’s disease rat model. Science. 2002;298:425–9.

Article  CAS  PubMed  Google Scholar 

Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet. 2007;369:1–9.

Article  Google Scholar 

Campos-Romo A, Ojeda-Flores R, Moreno-Briseño P, Vergara P, Segovia J, Carrillo-Ruiz JD, et al. Behavioral improvement in MPTP-treated nonhuman primates in the HALLWAY task after transfer of TH cDNA to host astrocytes. Acta Neurobiol Exp. 2012;72:166–76.

Google Scholar 

Goodwin LO, Splinter E, Davis TL, Urban R, He H, Braun RE, et al. Large-scale discovery of mouse transgenic integration sites reveals frequent structural variation and insertional mutagenesis. Genome Res. 2019;29:494–505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PWL, et al. Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest. 2021;131:e143780.

Hartmann A. Postmortem studies in Parkinson’s disease: the role of human postmortem studies in PD research. LLS SAS. Dialog Clin Neurosci. 2004;6:281–93.

Article  Google Scholar 

Tansey MG, Romero-Ramos M. Immune system responses in Parkinson’s disease: early and dynamic. Eur J Neurosci. 2019;49:364–83.

PubMed  Google Scholar 

Asanuma M, Miyazaki I, Murakami S, Diaz-Corrales FJ, Ogawa N. Striatal astrocytes act as a reservoir for L-DOPA. PLoS One. 2014;9:e106362.

Juorio AV, Li XM, Walz W, Paterson IA. Decarboxylation of l-Dopa by cultured mouse astrocytes. Brain Res. 1993;626:306–9.

Article  CAS  PubMed  Google Scholar 

Segovia J, Vergara P, Brenner M. Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental Parkinsonism. Gene Ther. 1998;5:1650–5.

Article  CAS  PubMed  Google Scholar 

Cortez N, Trejo F, Vergara P, Segovia J. Primary astrocytes retrovirally transduced with a tyrosine hydroxylase transgene driven by a Glial-Specific promoter elicit behavioral recovery in experimental Parkinsonism. J Neurosci Res. 2000;59:39–46.

Article  CAS  PubMed  Google Scholar 

Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 2013;31:827–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015;517:583–8.

Article  CAS  PubMed  Google Scholar 

Chavez A, Tuttle M, Pruitt BW, Ewen-Campen B, Chari R, Ter-Ovanesyan D, et al. Comparison of Cas9 activators in multiple species. Nat Methods. 2016;13:563–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Yin C, Zhang T, Li F, Yang W, Kaminski R, et al. CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep. 2015;5:1–14.

Google Scholar 

National Research Council (U.S.) Committee for the Update of the Guide for the Care and Use of Laboratory Animals., Institute for Laboratory Animal Research (U.S.). Guide for the care and use of laboratory animals. 8th ed. Washington (DC): National Academies Press (US); 2011. 220.

Erlij D, Acosta-García J, Rojas-Márquez M, González-Hernández B, Escartín-Perez E, Aceves J, et al. Dopamine D4 receptor stimulation in GABAergic projections of the globus pallidus to the reticular thalamic nucleus and the substantia nigra reticulata of the rat decreases locomotor activity. Neuropharmacology. 2012;62:1111–8.

Article  CAS  PubMed  Google Scholar 

Gu MJ, Jeon JH, Oh MS, Hong SP. Measuring levels of biogenic amines and their metabolites in rat brain tissue using high-performance liquid chromatography with photodiode array detection. Arch Pharm Res. 2016;39:59–65.

Article  CAS  PubMed  Google Scholar 

Cruz-Trujillo R, Avalos-Fuentes A, Rangel-Barajas C, Paz-Bermúdez F, Sierra A, Escartín-Perez E, et al. D3 dopamine receptors interact with dopamine D1 but not D4 receptors in the GABAergic terminals of the SNr of the rat. Neuropharmacology. 2013;67:370–8.

Article  CAS  PubMed  Google Scholar 

Guerrero-Cázares H, del Alatorre-Carranza MP, Delgado-Rizo V, Duenas-Jimenez JM, Mendoza-Magana ML, et al. Dopamine release modifies intracellular calcium levels in tyrosine hydroxylase-transfected C6 cells. Brain Res Bull. 2007;74:113–8.

Article  PubMed  Google Scholar 

Paxinos G, Watson C, The rat brain, in stereotaxic coordinates. San Diego: Academic Press; 1997.

Hudson JL, van Horne CG, Strömberg I, Brock S, Clayton J, Masserano J, et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 1993;626:167–74.

Article  CAS  PubMed  Google Scholar 

Song JJ, Oh SM, Kwon OC, Wulansari N, Lee HS, Chang MY, et al. Cografting astrocytes improves cell therapeutic outcomes in a Parkinson’s disease model. J Clin Investig. 2018;128:463–82.

Article  PubMed  Google Scholar 

Björklund A, Dunnett SB. The amphetamine induced rotation test: a re-assessment of its use as a tool to monitor motor impairment and functional recovery in rodent models of Parkinson’s disease. J Parkinsons Dis. 2019;9:17–29.

Article  PubMed  PubMed Central  Google Scholar 

Su RJ, Zhen JI, Wang W, Zhang JL, Zheng Y, Wang XM, et al. Time - course behavioral features are correlated with Parkinson’s disease - associated pathology in a 6 - hydroxydopamine hemiparkinsonian rat model. Mol Med Rep. 2018;17:3356–63.

CAS  PubMed  Google Scholar 

Landers MR, Kinney JW, Van Breukelen F. Forced exercise before or after induction of 6-OHDA-mediated nigrostriatal insult does not mitigate behavioral asymmetry in a hemiparkinsonian rat model. Brain Res. 2014;1543:263–70.

Article  CAS  PubMed  Google Scholar 

Drucker-Colín R, García-Hernández F. A new motor test sensitive to aging and dopaminergic function. J Neurosci Methods. 1991;39:153–61.

Article  PubMed  Google Scholar 

Paxinos G, Watson C. The rat brain in stereotaxic coordinates. London: Academic Press; 2007.

Iyer V, Venkiteswaran K, Savaliya S, Lieu CA, Handly E, Gilmour TP, et al. The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias. Neurobiol Dis. 2021;159:105491.

Schlachetzki JCM, Marxreiter F, Regensburger M, Kulinich A, Winner B, Winkler J. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson’s disease. Restor Neurol Neurosci. 2014;32:447–62.

CAS  PubMed  Google Scholar 

Gándara C, Affleck V, Stoll EA. Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to good manufacturing practice. Hum Gene Ther Methods. 2018;29:1–15.

Article  PubMed  PubMed Central